PMCPA Breach Statistics

Cases by Therapy Area

Based on 1,752 of 1,752 total cases (100% — only cases with a therapy area assigned are shown).

How to read this: Bar length = total cases for that therapy area relative to the highest-volume area. Solid colour = confirmed breaches (upheld/partially upheld). Faded = total volume. % Upheld = what proportion of cases resulted in a confirmed breach finding. Red (>20%) = high breach rate · Amber (10–20%) = moderate · Green (<10%) = lower risk.

Other

360 cases 62 breached 17%

2006–2024 · 298 not upheld

Oncology

218 cases 26 breached 12%

2005–2024 · 192 not upheld

Cardiovascular

189 cases 23 breached 12%

2006–2024 · 166 not upheld

Respiratory

178 cases 33 breached 19%

2006–2024 · 145 not upheld

CNS & Neurology

169 cases 36 breached 21%

2006–2024 · 133 not upheld

Infectious Diseases

115 cases 17 breached 15%

2005–2024 · 98 not upheld

Diabetes

114 cases 18 breached 16%

2006–2024 · 96 not upheld

Rare Diseases

104 cases 23 breached 22%

2006–2024 · 81 not upheld

Immunology & Rheumatology

84 cases 19 breached 23%

2006–2024 · 65 not upheld

Dermatology

67 cases 19 breached 28%

2006–2024 · 48 not upheld

Obesity & Weight Management

63 cases 12 breached 19%

2006–2024 · 51 not upheld

Musculoskeletal & Bone

60 cases 10 breached 17%

2006–2022 · 50 not upheld

Ophthalmology

31 cases 3 breached 10%

2007–2024 · 28 not upheld

% Upheld >20% — high breach rate 10–20% — moderate <10% — lower risk ⓘ "Upheld" = PMCPA finding of breach confirmed (upheld or partially upheld). "Not upheld" = no breach found.

Top 25 Companies by Case Volume

Based on 1,736 of 1,752 total cases (99% — cases where the company is the named respondent).

ⓘ Company Intelligence reports count all cases where the company appears (as complainant or related party) and will show higher totals than this table.

# Company Cases Upheld % Upheld

GSK / GlaxoSmithKline

99 12 12%

AstraZeneca

70 9 13%

Sanofi

46 7 15%

Pfizer

46 6 13%

Eli Lilly

38 4 11%

Roche

38 4 11%

Novo Nordisk

35 2 6%

Novartis

35 2 6%

Boehringer Ingelheim

33 4 12%

MSD / Merck Sharp & Dohme

33 4 12%

Bayer

28 5 18%

Janssen

26 7 27%

Allergan

21 1 5%

Takeda

20 1 5%

Lundbeck

18 3 17%

Leo Pharma

16 0 0%

Napp

16 1 6%

Daiichi Sankyo

15 0 0%

Merck Serono

13 1 8%

Shire

11 1 9%

Chiesi

11 2 18%

ProStrakan

11 1 9%

AbbVie

11 5 45%

Ferring

10 2 20%

Otsuka

10 2 20%

Case Volume by Year (2015–present)

Based on 970 of 1,752 total cases (2015 onwards — older cases exist in the database but are excluded from this trend view).

How to read this: Each bar = one calendar year. Number above = total cases. Light blue = all PMCPA cases that year. Dark blue = confirmed breaches (upheld or partially upheld).

2015

2016

2017

109

2018

123

2019

116

2020

117

2021

104

2022

125

2023

2024

Total cases

Confirmed breaches

Study the cases behind the numbers

Browse the full PMCPA case library with AI summaries, podcasts and videos — searchable by company, therapy area and outcome.

Browse Case Library →

PMCPA Breach Statistics

Cases by Therapy Area

Top 25 Companies by Case Volume

Case Volume by Year (2015–present)

Study the cases behind the numbers

AQP Flagship Path — the complete UK ABPI signatory programme

📰 Weekly PMCPA Case Breakdown